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ABSTRACT

By Yiyuan Wang
University of the Pacific
2022

Aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor that regulates
biological responses to planar aromatic hydrocarbon. AHR activates gene transcription by
binding to its corresponding enhancer with its partner-aryl hydrocarbon receptor nuclear
translocator (ARNT). In addition, this receptor has been shown to regulate xenobioticmetabolizing enzymes such as cytochrome P450. AHR exists widely in body tissues and affects
bioactivation of carcinogenic compounds, T cell differentiation, fatty acid synthesis, cell
proliferation, hematopoietic stem cell differentiation, respiratory reactivity, and insulin
sensitivity. Although the precise mechanism illustrating the endogenous AHR function remains
unclear, there has been intense interest in exploring AHR as a potential target for the treatment of
diseases such as cancer and autoimmune diseases.
It is known that mouse ahr d-allele possesses low ligand-binding affinity, whereas mouse
ahr b-allele has a higher ligand-binding affinity. The d-allele functions more similarly to human
AHR than the b-allele, which is most commonly studied. Human AHR can be rather difficult to
study since it is relatively unstable and less sensitive to some ligands in vitro. Thus we generated
a deletion construct which has the ligand-binding domain of human AHR and hoped that the
expression yield could be increased.
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Here, I present the process and the results of expressing the mouse full-length b-allele of
AHR and the human AHR ligand binding domain (LBD, amino acids 108 to 400) in Pichia
pastoris. A higher enrichment of the b-allele and LBD was observed in wild-type yeast (yJC100)
strain when compared to the protease-deficient yeast (ySMD1163) strain. This observation was
consistent with the increased copy number in the wild-type strain. Although the LBD transcript
was detected in both the wild-type and protease-deficient strains, the LBD protein was only
detected in the wild-type strain.
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CHAPTER 1: INTRODUCTION

1.1 The Aryl Hydrocarbon Receptor (AHR)
Aryl hydrocarbon receptor (AHR) is a protein transcribed from ahr gene, which is
included in biological regulatory responses to planar aromatic hydrocarbons by specific ligands.
Since it is a ligand-activated transcription factor, it activates the transcription of genes by binding
to the corresponding heterodimer, which is composed of AHR and aryl hydrocarbon receptor
nuclear translocator (ARNT) composition.1,2
In the canonical signaling pathway (XRE), the activation of AHR is due to the binding of
exogenous or endogenous ligands, resulting in nuclear translocation and coordinated recruitment
with ARNT protein to XRE induction. Without ligand binding, the AHR stayed in the cytoplasm
and bounded with the chaperone proteins like HSP90, p23, and ARA9. After binding and
activating with the corresponding ligand, it is speculated that AHR undergoes a conformational
change in the PAS-A domain, which will help the nuclear translocation, chaperone protein
dissociation, and the dimerization of AHR and ARNT through the PAS-A region.3-5,7 Once it
enters the nucleus, AHR dissociates from chaperone proteins and binds to ARNT to form a
heterodimer protein complex. At the same time, the ligand-induced conformational changes in
the PAS-A region will contribute to the AHR and ARNT dimerization.6,7 The whole process of
canonical signaling path is shown in Figure 1. The AHR signal will be inhibited by one of the
following mechanisms: the first was the induction of CYP1A1 and the clearance of ligand
metabolism; the second was the expression of AHR inhibitor (ahrr); the last was the degradation
of AHR by 26S proteasome. Therefore, in many studies, we can study the mechanism of AHR
by inhibiting the signal pathway of AHR.
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Figure 1. The Canonical Signaling Pathway (XRE) of AHR.

AHR is widely in various tissues of the human body. As a ligand-activated transcription
factor, it is involved in many crucial exogenous cytochrome P450 enzymes. Also, it participates
in many biological processes in the body, such as its biological activation of carcinogenic
compounds, T cell differentiation, fatty acid synthesis, cell proliferation respiratory effects.7-9
Researchers found that it not only mediates the toxicity of various environmental toxicants but
also plays a vital role in cell proliferation, differentiation, and human immune regulation.8-11
Although the exact mechanism of endogenous AHR function is not entirely understood,
researchers have always been interested in using AHR as a potential target for the treatment of
diseases such as cancer and autoimmune diseases.
AHR is involved in various essential cell cycle regulation and homeostasis signal
transduction pathways so that AHR can be acted as a molecular target for cancer therapy. If
combined with CYP1A1, it plays a role in the detoxification of environmental carcinogenesis. It
prevents metabolic activation of mixtures of diets containing cancer activity, cancer progression,
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or prevention based on the balance of activation/detoxification of pro-carcinogens and
extrahepatic metabolism of natural dietary products.13 Increased AHR expression in lung
adenoma cells can increase intracellular oxidative stress and promote cell growth, suggesting that
interfering with AHR expression may prevent the early development of lung adenomas.14, 16
TCDD and a non-toxic AHR agonist induce the expression of the cell cycle regulation-dependent
kinase inhibitor p21, causing cell growth inhibition in pancreatic cancer with high AHR
expression, suggesting that increasing AHR expression may provide a therapeutic target for
pancreatic cancer.15
The expression of AHR in most types of immune cells and the promoter regions of many
genes regulating immune responses demonstrates the importance of this receptor in the immune
process.17 For example, tryptophan metabolism by microorganisms in the gut produces AHR
agonists to support the development and maintenance of type 3 innate lymphocytes (ILC3) in the
gut, while ILC3 as the innate immune system corresponds to the CD4 T of the adaptive immune
system cells, the latter mainly produce IL-17 and IL-22. AHR signaling is also required for the
maintenance of IL-22-producing intraepithelial lymphocytes (IELs), which are involved in
mucosal wound healing and antimicrobial peptides (AMPs) production in intestinal epithelial
cells (IECs).19 The AhR-IL-22 signaling pathway in the gut plays a vital role in host defense
against microbial pathogens and promotes disease tolerance to limit deleterious effects. Weak
activation of AhR supports a pro-inflammatory response (Th17/22), whereas strong activation of
AhR promotes the induction of tolerogenic dendritic cells (DCs) and regulatory T cells
(Tregs).18-21
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1.2 Functional Domain of Human AHR
AHR protein is a member of the basic helix-loop-helix/Per-Arnt-Sim (bHLH/PAS)
family of transcription factors and contains multiple domains with important functions.7,12 As
shown in Figure 2, the common entity bHLH domain of multiple transcription factors are located
at the N-terminal of the protein, which has two domains with unique functions and is highly
conserved among the family. One is the basic region (b), which is involved in the binding of
transcription factors and DNA. The second is the helix-loop-helix (HLH) region, which
promotes protein-protein interaction.22 The next PAS domain contains PAS-A and PAS-B,
which are fragments of 200-350 amino acids and have high sequence similarity with PAS protein.
In addition, the PAS domain supports specific secondary interactions with other proteins
containing the PAS domain, such as AHR and ARNT, thus forming dimer and heteropolymer
protein complexes.23 The ligand-binding site of AHR is resided in the PAS-B domain and
contains several conserved residues, which are essential for ligand binding. Finally, the
glutamine-rich (Q-rich) domain is located in the C-terminal region of the protein and is involved
in the recruitment and transactivation of coactivators.24,25 We are interested in the properties of
the AhR domain, especially the ligand binding domain (LBD), as shown in Figure 2.
AHR can bind and be activated by a structurally diverse array of both synthetic and
natural compounds through the ligand binding domain. However, resolving the full-length threedimensional structure of AhR has always been an arduous task. Despite the efforts of scientists
to achieve this goal, the entire AhR protein does not yet have a complete structure. Until 2013,
the first X-ray diffraction based AHR 3D structure of the PAS-A homodimer structure obtained
from recombinant E. coli expression was reported for the mouse PAS-A domain (residues 110 to
267); the resolution is 2.55 Å (PDB ID: 4M4X).26 Another two other AhR structures were
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reported in 2017, containing multiple AhR domains and showing distinct interactions between
AhR and its dimerization partner ARNT and its interaction with both DNA strands. The two
structures reveal the complex formation between the bHLH and PAS-A domains of human AhR
and their interactions with ARNT and DNA.27-29 However, neither of these two subdomains is
included in this architecture due to the observed high flexibility of the AhR PAS-B domain and
transaction domain (C-side). Therefore, people usually developed LBD homology modeling
since there aren’t enough experimentally determined structures under the molecular level. With
the availability of extensive structural information on homologous PAS-containing proteins, a
reliable model of the mouse AhR PAS-B domain was developed by comparative modeling
techniques.30 The PAS domain structures of the functionally related hypoxia-inducible factor 2R
(HIF-2R) and AhR nuclear transporter (ARNT) proteins, which share the highest degree of
sequence identity and similarity with AhR, usually were selected as templates for the
development of two Models. To confirm the characteristics of the modeling domains, the effect
of point mutations at selected residue positions on TCDD binding to AhR and TCDD-dependent
transformation and DNA binding was analyzed. Mutagenesis and functional analysis results are
consistent with the proposed model and confirm that the cavity modeled inside the domain is
involved in ligand binding. In addition, the physicochemical characterization of some residues
and their mutants and the effect of mutagenesis on TCDD and DNA binding have also shown
some critical features required for ligand binding and mAHR activation at the molecular level,
thus enabling deep learning.31-33 But more reliable information on the structural characteristics
of the AhR LBD will only be obtained when the structures of homologous proteins with higher
sequence identity to AhR become available.
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Figure 2. Human AHR functional domain

1.3 Similarity of Mouse AHR and Human AHR
As shown in Figure 3, the amino acid sequence of mouse AHR b-allele and human AHR
has a high similarity. The amino acid sequence similarity is as high as 89% for the ligand
binding domains. However, there are significant differences in dioxin reactivity among different
species with structurally distinct AHRs. For example, studies have shown at least a 1000-fold
difference in TCDD tolerance between the more sensitive guinea pig and tolerant hamster
species. Since an alanine residue in the ligand binding domain (A375 corresponding to the V381
of hAHR), the mouse AHR b-allele (mAHRb) has a ten-fold higher affinity for AHR ligands
(TCDD) when it compared with the human AHR (hAHR). However, the affinity of mouse AHR
d-allele for AHR ligand is similar to human AHR.34,35
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Figure 3. Comparison of human and mouse AHR protein structure34

Therefore, a truncated protein hAHR aa108-400 will be generated for studying the ligand
binding domain of hAHR, which contains the PAS-B domain of human AHR and several
conserved amino acid residues.
1.4 Different Expression Systems of AHR
Information for protein synthesis is stored in DNA and decoded through the process of
transcription to produce messenger RNA (mRNA). The information encoded by the mRNA is
then translated into protein. Transcription refers to the transfer of information from DNA to
mRNA, while translation is the synthesis of proteins based on the sequences specified by the
mRNA. At the same time, protein synthesis and regulation depend on functional requirements in
the cell. Researchers often need to construct functional proteins of interest to study how specific
proteins regulate biology. Given the size and complexity of proteins, chemical synthesis is not
viable for this work. Also, living cells and their cellular machinery are often used as factories to
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build and construct proteins based on genetic templates provided. DNA is easily synthesized or
constructed in vitro using established recombinant DNA technologies compared with proteins.
Thus, gene-specific DNA templates can be constructed to serve as templates for protein
expression, with or without an additional reporter or affinity tag sequences. Proteins produced
from this DNA template are called recombinant proteins. Strategies for recombinant protein
expression include transfecting cells with a template-containing DNA vector and then culturing
the cells so that they transcribe and translate the desired protein. The cells were then lysed to
extract the expressed protein for subsequent purification. The choice of system depends on the
type of protein, requirements for functional activity and desired yield. These expression systems
are summarized below and include mammalian, insect, yeast, bacterial, etc. expression systems.
Each system has advantages and challenges, choosing the right system for a specific application
is vital for the successful expression of recombinant proteins.
According to different expression systems, the expression products of AHR are also
different. Protein expression products are growing rapidly for expression systems such as E.
coli and bacteria. However, their applications are limited by the inability to fold correctly and
perform proper post-translational modification of mammalian proteins. However, due to its low
expression cost, simplicity and convenience, short growth cycle, and high yield, it is still one of
the essential expression systems of AHR. More than twenty years ago, our laboratory
overexpressed the AHR protein in the baculovirus expression system. As a result, it expresses
relatively high-yield recombinant proteins, and the expressed AHR is functional, which can bind
to ligands, form dimers, and activate DRE signaling pathways. However, since baculovirus must
be produced regularly through the low multiplicity of infection (MOI) of insect cells, cloned
high-titer virus strains may cause baculovirus genome mutations, thereby reducing the yield of
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recombinant proteins and possibly changing the nature of the recombinant proteins.36,37 If we
want long-term stable expression, it is clear that the baculovirus expression system does not
provide stable and complete support. For mammalian expression systems, AHR can stabilize
long-term expression and has post-translational modifications of proteins. However, due to its
high cost, low protein yield, and long cultivation cycle. Therefore, it does not apply to my
experimental project. Next, Pichia pastoris expression system will be introduced in detail and it
also will be used in expressing AHR recombinant protein.
1.5 Pichia pastoris Expression System
Pichia pastoris is a eukaryote. It has the ability to modify post-translational recombinant
proteins, such as producing biologically active molecules, folding correctly, forming disulfide
bonds, and glycosylation.38 At the same time, Pichia pastoris is a methylotrophic yeast that can
metabolize methanol as its single carbon source. Methanol is oxidized to formaldehyde during
methanol metabolism. However, the alcohol oxidase that catalyzes the oxidation of methanol
has a poor affinity for oxygen. Therefore, in the process of metabolizing methanol, Pichia
pastoris must produce a large number of enzymes to metabolize methanol. At the same time,
promoters produced by regulatory enzymes are therefore used to drive the expression of
heterologous proteins in Pichia pastoris. The two genes encoding alcohol oxidase in Pichia
pastoris are AOX1 and AOX2. In general, most of the enzyme's activity depends on the AOX1
gene.39-41 And its expression is primarily controlled by methanol. Therefore, the target gene
inserted into the plasmid with the AOX1 promoter can be used to induce the expression of the
desired heterologous protein. Following the published paper from our lab, the Pichia pastoris
expression system can be developed to overexpress functional AHR proteins with higher yield
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stably and lower cost compared to the baculovirus insect and mammalian cell expression
system.42
To summarize, the hypotheses for the project are:
1. Purified mouse full-length b-allele of AHR will be enriched in Elute 1 (E1) after Pichia
expression and metal affinity purification.
2. Higher copy number will be selected by higher Zeocin concentration and higher protein
expression will be detected in higher copy number strain.
3. Purified aa108-400 human AHR will be enriched in Elute 1 (E1) after Pichia expression and
metal affinity purification in both strains.
To test these hypotheses, there are three specific aims:
1. Separately clone a stable codon-optimized mouse b-allele AHR and human aa108-400 AHR
genes, with alcohol oxidase (AOX) promoter, c-myc and 6-his tag at the end of genes, into
Pichia pastoris genome to express mouse b-allele AHR and human aa108-400 AHR proteins.
2. Cobalt resin will be used to enrich the mouse b-allele AHR and human aa108-400 AHR
proteins.
3. Relative copy numbers of mouse b-allele AHR and human aa108-400 AHR genes will be
determined by qPCR.
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CHAPTER 2: EXPRESSION MOUSE FULL-LENGTH B ALLELE AHR IN PICHIA
PASTORIS

2.1 Successful pPICZ-B Mouse Full-length b-allele AHR Plasmid Construct Creation
2.1.1 pPICZ plasmid for cloning. Primers were designed to amplify the nucleotides
sequence of mouse full-length b-allele AHR from the incorrect construct pPICZ-A mouse fulllength b-allele AHR, which contains a stop codon. The pPICZ A, B, & C Pichia vectors usually
are designed for simple cloning and selection, high-level expression, and rapid detection and
purification of the recombinant protein. In addition, these vectors contain the Zeocin™
resistance gene to select integrated strains after electroporation directly. The recombinant
protein is expressed as a fusion protein containing the c-myc epitope and a polyhistidine (6xHis)
tag. The vector has multiple cloning sites to insert foreign genes and allows high-level
methanol-induced expression of the target gene in Pichia pastoris. pPICZ A, B, and C Map as
shown in Figure 4.
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Figure 4. Map of pPICZ A, B, and C.

The corresponding restriction enzyme was used to cut the pPICZ-A mouse full-length ballele AHR through EcoRI and Kpnl. Gel electrophoresis (Figure 5 a & b) shows the sequence
of mouse AHR full-length b-allele is around 2.4kb through Polymerase Chain Reaction (PCR),
which is consistent with the calculation result of our nucleotides.

25

Figure 5. Construct pPICZ-B mouse full-length b-allele AHR plasmid. (a) Cutting pPICZ-A
mouse full-length b-allele AHR through EcoRI and Kpnl. Gel electrophoresis shows the
sequence of mouse full-length b-allele AHR is around 2.4kb. (b) Amplifying DNA sequence of
mouse full-length b-allele AHR. Gel electrophoresis shows the appropriate size of amplification
products. (1. 0.1ng DNA cut pPICZ-A full-length b-allele mouse AHR as template 2. 1ngDNA
cut pPICZ-A mouse full-length b-allele AHR as template 3. 0.1ng DNA uncut pPICZ-A mouse
full-length b-allele AHR as template 4. 1ng DNA uncut pPICZ-A mouse full-length b-allele
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(Figure 5 Continued)
AHR as template 5. 0.1ng DNA cut pPICZ-A mouse full-length b-allele AHR as a template
without PCR 6. 1ngDNA cut pPICZ-A mouse full-length b-allele AHR as a template without
PCR 7. 1ngDNA uncut pPICZ-A mouse full-length b allele AHR as a template without PCR) (c)
Linearized empty pPICZ-B plasmid through Pml I. Gel electrophoresis shows the appropriate
size of the linearized empty pPICZ-B plasmid.

2.1.2 pPICZ-B mouse full-length b-allele AHR plasmid construct creation. Gibson
Assembly allows the successful assembly of multiple DNA fragments, regardless of fragment
length or end compatibility. This method has been successfully used to assemble
oligonucleotides, DNA with varying overlaps (15-80 bp), and fragments hundreds of kilobases
long and has been rapidly adopted by the synthetic biology community due to its ease of
manipulation. Flexibility and applicability for use with large DNA constructs. Furthermore,
restriction digestion of DNA fragments is not required after PCR. Meanwhile, the backbone
vector can be digested or synthesized by PCR. Because it requires fewer steps and fewer
reagents, it is cheaper and faster than traditional cloning protocols. Gibson Assembly allows the
insertion of one or more DNA fragments into almost any location in a linearized vector and is
independent of the presence of restriction sites in the specific sequence to be synthesized or
cloned. Larger numbers of DNA fragments can be ligated with higher efficiency in a single
reaction than traditional methods. The process of Gibson Assembly is shown in Figure 6. Figure
5 b and c show the DNA fragment and Linear vector, respectively.
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Figure 6. Overview of the Gibson Assembly Cloning Method

In order to get enough construct plasmid, we inserted the construction to BL-21 strain
through electroporation as shown in Figure 7.
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Figure 7. Electroporation Transformation

2.1.3 Check pPICZ-B mouse b-allele AHR plasmid construct. We choose the Stu I
cut the plasmid since there are only two restriction enzyme sites on the pPICZ-A or pPICZ-B
mouse full-length b-allele AHR plasmid construct. One is on the sequence of mAHRb, and
another is on the vector. Stu I located on nucleotides 1566 (mAHRb sequence) and 4951 (vector)
of pPICZ-A mouse full-length b-allele AHR construct, which has another 270 bp on the vector
end compared to pPICZ-B mouse full-length b-allele AHR construct. As shown in Figure 8, we
will see two bands for each construct after double digestion with the above information. For the
pPICZ-A mouse full-length b-allele AHR construct, the band will be 3.4 kb and 2.5 kb. Also, for
the pPICZ-B mouse full-length b-allele AHR construct, the band will be 3.4 kb and 2.3 kb.
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Figure 8. Detection of construct plasmid (pPICZ-B mAHRb) after electroporation. (a) Double
digestion of eight selected colonies through Stu I. The homemade solution is used to extract the
constructed plasmid. (b) Double digestion of colony 4 by Stu l. The miniprep kit is used to
extract the constructed plasmid.

2.2 Transformation Into Yeast Strains
To promote integration, we linearize the pPICZ-B mouse b-allele AHR construct at the
Sac I enzyme site within the 5’AOX1 region. Then transform the pPICZ-B mouse full-length ballele AHR plasmid construct into both wild-type (yJC100) strain and protease-deficient
(ySMD1163) strain through electroporation. Figure 9 shows the linearized plasmid. We also
can check the result of transformation easily by colony PCR as shown in Figure 10.
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Figure 9. Linearizing pPICZ-B-mAHRb through Sac I.
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Figure 10. Detection of recombinant plasmid (pPICZ-B mAHRb). After electroporation of the
pPICZ-B mouse full-length b-allele AHR into two types of yeast strains. We use specific
primers to detect target DNA by colony PCR.

2.3 Mouse Full-length b-allele AHR Induction Time Determination
In an effort to identify an optimal induction time for recombinant protein, we did a time
course for 72 hours of both yeast strains. Normalization expression volume amount of protein
for Coomassie blue stain and Western blot, we can see the highest protein level in 3 hours
induction time of WT strain (Figure 11), 6 hours induction time of protease-deficient strain
(Figure 12). We will choose the 6 hours as idea induction time for further study protein
expression.
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Figure 11. Induction time course of mouse full-length b-allele AHR in yJC100. (a) Collect
different time point cultures and harvest protein. (Left) Coomassie blue stain (Right) Western
blot. Use SA210 antibody to detect mouse full-length b-allele AHR. (b) Same process as (a).
(Left) Load 10μl sample for each line. (Right) Load 8μl sample for each line.
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Figure 12. Induction time course of mouse full-length b-allele AHR in ySMD1163. (a) Collect
different time point cultures and harvest protein. (Left) Coomassie blue stain (Right) Western
blot. Use SA210 antibody to detect mouse full-length b-allele AHR. (b) Same process as (a).
(Left) Load 10μl sample for each line. (Right) Load 8μl sample for each line.

2.4 Mouse AHR Expression and Purification
The Pichia expressed mouse full-length b-allele AHR protein was detectable by Western
blot but not by Coomassie Staining (Figure 13). The amount of mouse full-length b-allele AHR
protein is such less amount that it cannot be seen on Coomassie Staining. However, the antibody
is so sensitive that we can see a strong band on the membrane of Western blot. We can see there
has a significant band of E1 in both Pichia strains (Figure 13). After three times dependent
experiments, we can see a higher amount of Load and E1 in the WT strain compared with the
protease-deficient strain (Figure 14.).
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Figure 13. Expression and purification of mouse full-length b-allele AHR in two types of yeast
strains. Use 2.6 ml load for purification. Collect flow-through (FT), wash, elute 1(E1), E2, and
analysis. Use 10μl for Coomassie blue stain analysis and 8μl for western blot. SA210 antibody
to detect mouse full-length b-allele AHR. (Left) Coomassie blue stain (Right) Western blot.
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Figure 14. Expression and purification of mouse full-length b-allele AHR in two types of yeast
strains. Repeat the whole process three times. Use 7μl Load and E1, 3μl hAHR for Western blot.
SA210 antibody to detect mouse full-length b-allele AHR. (a) yJC100 strain (b) ySMD1163
strain.

2.5 Relative Copy Number of Mouse Full-length b-allele AHR
We use the different concentrations of Zeocin (from 100μg/μl to 1000μg/μl) to select the
transformed yeast strain. We assume that the strain will obtain much resistance when integrated
more copies into the genome. Mouse full-length b-allele AHR in WT (yJC100) strain can grow
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up to 1000 μg/μl Zeocin YPD plate, but the mouse full-length b-allele AHR in protease-deficient
(ySMD1163) only can grow on 500μg/ μl zeocin YPD plate. I use the actin as the reference gene
to plot the curve of Log (Cq) vs. template amount. Since we already know actin has one copy in
yeast, we can conclude the relative copy number for yJC100 ( ~ 4 copies) and ySMD1163 ( ~ 3.2
copies), which is consistent with the higher Zeocin concentration will select the strain with
higher copies.

Figure 15. Relative copy number of mouse full-length b-allele AHR in WT (yJC100) and
protease-deficient (ySMD1163) strain.
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CHAPTER 3: EXPRESSION LIGAND BINDING DOMAIN OF HUMAN AHR IN PICHIA
PASTORIS

3.1 Successful pPICZ-B aa108-400 of Human AHR Plasmid Construct Creation
3.1.1 pPICZ-B aa108-400 of human AHR plasmid construct creation. Primers were
designed to amplify the nucleotides sequence of aa108-400 of human AHR from the full
sequence human AHR, which is inserted into the pPICZ-B vector. Gibson Assembly method
was used to ligate the pPICZ-B linearized vector (Figure 16 a) to aa108-400 hAHR DNA
sequence (Figure 16 b).

Figure 16. Construct pPICZ-B aa108-400 of human AHR plasmid. (a) Linearized empty pPICZB plasmid through Pml I. Gel electrophoresis shows the appropriate size of the linearized empty
pPICZ-B plasmid. PCR doesn’t work because the template of PCR (PL301 pPICZ-B-hAHR) is
not good enough to amplify. (b) Use a new pPICZ-B-hAHR extraction plasmid as a template.
Gel electrophoresis shows the PCR product (aa108-400 of hAHR)
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3.1.2 Check pPICZ-B aa108-400 of human AHR plasmid construct. We choose eight
colonies of pPICZ-B aa108-400 of human AHR after electroporation into the BL-21 strain.
EcoR I and Xho I will be used to do the double digestion of eight selected colonies. Gel
electrophoresis is shown in Figure 17.

Figure 17. Detection of recombinant plasmid (pPICZ-B aa108-400 of hAHR) after
electroporation. Double digestion of eight selected colonies. The homemade solution is used to
extract the plasmid.

3.2 Transformation Into Yeast Strains
Same as 2.2, the pPICZ-B aa108-400 hAHR plasmid construct was transformed into both
wild-type (yJC100) strain and protease-deficient (ySMD1163) strain through electroporation.
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Figure 18 shows the linearized plasmid. The result of transformation will be detected by colony
PCR as shown in Figure 19.

Figure 18. Linearizing pPICZ-B aa108-400 of hAHR through Sac I.
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Figure 19. Detection of recombinant plasmid (pPICZ-B aa108-400 of hAHR). After
electroporation of the pPICZ-B aa108-400 of hAHR into two yeast strains. We use the specific
primer to detect target DNA by colony PCR.

3.3 Expression and Purification of hAHR aa108-400.
3.3.1 Use SA210 to detect the hAHR aa108-400 in Western blot. SA210 is a
recombinant protein corresponding to aa 1-402 of the N-terminal AHR. So we need to know
whether SA210 picks the aa108-400 AHR band since we lost aa 1-107 of AHR. Here we use
MBP aa108-400 fusion protein to whether the results. The Maltose-binding protein (MBP) is
one of the most popular fusion partners to produce recombinant proteins in bacterial cells. MBP
allows one to use a simple capture affinity step on amylose-agarose columns, resulting in a
protein that is often 70-90% pure.43 Figure 20 shows the SA210 can pick up the MBP aa108-400.
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We also know that our lab did the full sequence AHR expression and purification in the
ySMD1163 strain. After repeating Dr. Yujuan. Zheng’s experiment, we got the results for
Figure 21.

Figure 20. SA210 antibody can be used to detect MBP aa108-400. We use hAHR as positive
and WT MBP as a negative control to see whether SA210 has good specificity to aa108-400 of
hAHR.
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Figure 21. Expression and purification of human AHR in ySMD1163. Use 2.6 ml load for
purification. Collect flow-through (FT), wash, elute 1(E1), E2, E3, and analysis. E1*(pi-pPICZB hAHR in 50% glycerol 6/20/17) as a positive control to see human AHR express success.

Unfortunately, we cannot find the significant band clearly when we use SA210 to purify
aa108-400 AHR in both strains, as shown in Figure 22. To further study the reasons, we first
compare the different Load and E1 in different strains. Figure 23 shows the strong band for
mouse AHR and full-length hAHR but not aa108-400 hAHR.
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Figure 22. Expression and purification of aa108-400 of hAHR in two types of yeast strains. Use
2.6 ml load for purification. Collect flow-through (FT), wash, elute 1(E1), E2, and analysis. Use
15μl for Coomassie blue stain and 10μl for western blot. SA210 antibody to detect 108-400 of
hAHR. (Left) Coomassie blue stain (Right) Western blot.

Figure 23. Comparison of different load and E1 through Western blot. SA210 antibody can be
used to detect aa108-400 of hAHR and mouse AHR.
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3.3.2 hAHR aa108-400 expression and purification. We know the pPICZ-B aa108400 hAHR integrates into the yeast genome since we do see the band in Colony PCR. Dr. LinCereghino provided us with another antibody, which is an anti c-myc antibody from the mouse.
Thank you for his advice, and we can see the strong bands of WT strain on Western blot, as
shown in Figure 24. But not any bands in ySMD1163. We did three times dependent purification
for aa108-400 hAHR in WT strain to see the relationship between the Load and E1, as shown in
Figure 25.

Figure 24. Expression and purification of aa108-400 of hAHR in two strains. Use 2.8 ml load
for purification. Collect flow-through (FT), wash, elute 1(E1), E2, E3, and analysis. E1*(pipPICZ-B hAHR) as a positive control to see human AHR express success. We use the c-myc
antibody to detect protein expression.
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Figure 25. Expression and purification of aa108-400 of hAHR in yJC100 (WT) yeast stains.
Repeat the whole process three times. Use the c-myc antibody to detect Pellet, Load, and E1 in
Western blot.

46

3.4 Relative Copy Number and Fold Change of aa108-400 hAHR
We use the different concentrations of Zeocin (from 100μg/μl to 1000μg/μl) to select the
transformed yeast strain. We assume that the strain will obtain much resistance when integrated
more copies into the genome as previously. The aa108-400 hAHR in WT (yJC100) strain can
grow up to 1000μg/μl Zeocin YPD plate, but the aa108-400 hAHR in protease-deficient
(ySMD1163) only can grow on 500μg/μl Zeocin YPD plate. The full-length hAHR was selected
by 100μg/μl before. I use the actin as the reference gene to plot the curve of Log (Cq) vs.
template amount. Since we already know actin has one copy in yeast, we can conclude the
relative copy number for yJC100 ( ~ 4 copies) and ySMD1163 ( ~ 2.9 copies) of the aa 108-400
hAHR, which is consistent with the higher Zeocin concentration will select the strain with higher
copies. But we still see full-length hAHR has a similar relative copy number with the aa108-400
hAHR in ySMD1163 (Figure 26). We also checked the messenger RNA level for aa108-400 in
both strains since no recombinant protein (aa108-400 hAHR) was expressed in the ySMD1163
strain. The result shows that the aa108-400 hAHR in the ySMD1163 has a higher mRNA level
than the WT strain, even though no recombinant protein was expressed (Figure 27).

47

Figure 26. Relative copy number of aa108-400 AHR in WT (yJC100) and protease-deficient
(ySMD1163) strain, together with full-length hAHR.

Figure 27. The mRNA levels of aa108-400 AHR in WT (yJC100) and protease-deficient
(ySMD1163) strain.
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CHAPTER 4: DISCUSSION

The AhR was discovered in 1976 by Dr. Poland as a dioxin-binding protein.44 AHR has
been shown to mediate many pathways involved in our immune systems, body function, and
others. Our lab studied AHR for many years, including its ligand, chaperon, signal pathway, and
expression system.
The first human AHR overexpression in baculovirus was more than thirty years ago.
Researchers in our lab also use baculovirus to express the AHR. For example, we use a
baculovirus system to express human AHR and ARNT.37 Other scientists also use the
baculovirus system to express rat AHR to study its ligand binding.36 Due to the nature of the
insect cells, it requires more times infection by cloned baculovirus to continually express
recombinant proteins with high titer viral stock since baculovirus will be consumed for a long
time expression.36 This will increase the possibility of the mutations for the baculovirus genome
over time, which might change the characteristic of the recombinant protein or lower the amount
of protein expression. We also use the bacterial expression system to express many deletion
constructs of human AHR. Bacteria usually express a high yield amount of AHR with economic
experiments, but it lacks post-translation. Our lab usually studies the function and signaling
pathway through the mammalian cells because of its time-consuming and expensive cost.
Therefore, my project focuses on the optimized Pichia expression system, which is relatively
reliable and performs much eukaryotic post-translational modification. In addition, the
transformed yeast cells, which can be made into glycerol stocks and stored at - 80°C, can be
continuously used to produce the recombinant proteins.
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Previous researchers in our lab had successfully expressed full-length hAHR in the
ySMD1163 strain. Unfortunately, the amount of soluble human AHR is still meager, and it is
hard to do further studies like ligand binding, x-ray crystal structure, and new ligand findings.
Therefore, we created the truncated protein of the AHR ligand-binding domain to see whether
we could increase the expression yield. The Pichia expression system makes it a better
alternative to obtain functional AHR for mechanistic studies. We also express mouse full-length
b allele of AHR since the affinity is different between mouse and human.
4.1 Expression of mouse full-length b-allele AHR in Pichia pastoris
AhR, a ligand-activated transcription factor, is formed in a stable complex by two
molecules, heat shock protein 90 (Hsp90), immunophilin-like AhR interacting protein (AIP, also
known as XAP2 and ARA9), and p23. The interaction of Hsp90 with human AhR is less stable
and requires the presence of molybdate in the buffer to stabilize the receptor/Hsp90 complex.45-47
That is, mouse AHR is more stable compared with human AHR, which is the reason for
expressing mouse AHR. We already know the amino acid sequence of mouse AHR and human
AHR has high similarities. However, there are significant differences in gene regulation,
recruitment of coactivators, and ligand affinity in mAHRb with hAHR.
We hypothesis that purified mouse full-length b-allele of AHR will enrich in Elute 1 (E1)
after Pichia expression and metal affinity purification. After the mouse full-length b-allele of
AHR transformed into both WT (yJC100) and protease-deficient (ySMD1163) strains. We see
the enrichment of mouse full-length b-allele of AHR in both strains, but the yield is not as we
expect high compared with the full-length human AHR in the ySMD1163 strain (Figure 22). I
also found it hard to make good quality ySMD1163 competent cells when using the traditional
method. Thanks to Dr. Lin-Cereghino for teaching me how to make fresh competent cells for
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both yeast strains. After the electroporation, the results of colony and qPCR told us that the
mouse full-length b-allele AHR integrated into the yeast genome successfully. Besides, the
higher Zeocin concentration selected a higher copy number, which is consistent with the protein
expression result (WT strain has a higher yield of protein expression). Generally, we would see
a more elevated amount of protein expression in protease-deficient since the protein cannot be
degraded when it has the same copy number. I would expect to see higher protein expression
yield when we selected the WT strain (mouse full-length b-allele AHR) to only grow on 500
μg/μl Zeocin but not 1000 μg/μl.

4.2 Expression of aa108-400 Human AHR (LBD) in Pichia pastoris
The aa108-400 human AHR contains the ligand binding domain (aa 217-390) of hAHR.
The ligand binding site of AHR is contained within the PAS-B domain and contains several
conserved residues critical for ligand binding. Modulation of the AHR function is primarily
conferred through interaction at the ligand binding domain using agonists and antagonists. And
why I choose the ligand binding domain when creating the truncated protein? There have several
reasons: 1) The function of this domain can be tested by ligand binding; 2) If we got enough
protein, we could have the crystal structure of ligand binding domain; 3) Study the binding
affinity. Our lab also expresses MBP aa108-400 of human AHR in E.coli successfully.
We hypothesis that purified aa108-400 human AHR will enrich in Elute 1 (E1) after
Pichia expression and metal affinity purification in both strains. Unfortunately, we do not see an
interesting recombinant protein in the ySMD1163 strain. The results of colony PCR and qPCR
show that the aa108-400 hAHR successfully transforms into the yeast genome. Therefore, in
order to see what happened, we measured the mRNA level for both strains. The result shows
that the aa108-400 hAHR in the ySMD1163 has a higher mRNA level than the WT strain, even
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though no recombinant protein was expressed. Therefore, we assume that aa108-400 of human
AHR (LBD) cannot be used as a template to generate protein, or the transcriptome is less stable
in the ySMD1163 strain. I was wondering why aa108-400 hAHR cannot be expressed in
ySMD1163. How about choosing another vector to insert the cDNA sequence into the yeast
genome? The idea result is to express an abundant amount of ligand binding domain to be able
to generate a crystal structure for x-ray crystallography and test the function by ligand binding.
4.3 Conclusion and Future Work
4.3.1 Conclusion For mouse full-length b-allele of AHR expression, we can conclude: 1)
the higher enrichment E1 of mouse full-length b-allele AHR in WT strain; 2) higher copy
number leads to higher amount soluble mouse full-length b-allele AHR protein in WT strain.
For aa 108-400 hAHR expression, we can conclude: 1) aa108-400 of human AHR (LBD)
can be expressed and purify in the WT strain; 2) aa108-400 of human AHR (LBD) cannot be
used as a template to generate protein, or the transcriptome is less stable in the ySMD1163 strain.
4.3.2 Future work Further modification of this Pichia expression system is needed to
obtain a more abundant and purer recombinant protein. And the function of mouse b-allele AHR
and aa108-400 hAHR is needed to be studied.
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CHAPTER 5: MATERIALS AND METHODS

5.1 Material
All chemicals and ingredients to prepare bacteria and yeast media (LB, YPD, BMGY,
and BMMY) were purchased from Thermo Fisher Scientific (Hampton, NH) or Sigma Aldrich
(St. Louis, MO). All oligonucleotides, Zeocin, otherwise specified, were purchased from
Thermo Fisher Scientific (Hampton, NH). All restriction enzymes were purchased from New
England Biolabs (Ipswich, MA). Anti-AHR SA210 rabbit IgG was purchased from Enzo Life
Sciences (Farmingdale, NY). Anti-c-myc mouse IgG was purchased from Santa Cruz
Biotechnology (Dallas, TX, USA). IRDye800 donkey secondary IgG was purchased from LICOR (Lincoln, NE). IRDye680-conjugated DRE was purchased from Integrated DNA
Technologies (San Diego, CA). The Gene Art codon-optimized human AHR sequence (GAhAHR) was purchased from Life 34 Technologies (Thermo Fisher Scientific, Grand Island, NY).
Cobalt agarose beads were purchased from Gold Biotechnology (St. Louis, MO). The Gibson
assembly kit was purchased from New England Bioabs (Ipswich, MA). The Colony PCR master
mix was purchased from Lucigen Corporation (Middleton WI). The pPICZ-B plasmid and the
Pichia strains (ySMD1163 and yJC100) were gifts from Dr. Geoff Lin-Cereghino (University of
the Pacific). Western blot analyses were performed using an LI-COR Odyssey imaging system
(Lincoln, NE). Electroporation was performed using an Eppendorf 2510 electroporator (Edison,
NJ). Cells pellets were homogenized using Bullet Blender Storm 24 (Troy, NY). Media and
culture plates were made by following the recipes from “Pichia Expression Kit Version L”
and are briefly introduced as below. YPD (Yeast extract Peptone Dextrose) plate: 1% yeast
extract, 2% peptone, 2% dextrose, 2% Agar. BMGY (Buffered Glycerol-complex Medium): 1%
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yeast extract, 2% peptone, 10% 1 M potassium phosphate buffer at pH 6.0, 1.34% YNB (Yeast
Nitrogen Base), 4×10-5 % biotin, 1% glycerol. BMMY is the same as BMGY except for
replacing 1% glycerol with 0.5% methanol. ZymoPURE II Plasmid Maxiprep kit and Direct-zol
RNA Miniprep kit were purchased from Zymo Research (Irvine, CA, USA). MMLV highperformance reverse transcriptase was purchased from Epicentre (Madison, WI, USA). iTaq
Universal SYBR Green Supermix was 103 purchased from Bio-Rad (Hercules, CA, USA).
5.2 Methods
5.2.1 Polymerase chain reaction (PCR). Mouse AHR (pPICZ-A mouse AHR) and
full-length human AHR (pPICZ-B hAHR) were obtained from the Dr. William Chan lab. Mouse
AHR template from two restriction enzyme reactions (10 μl pPICZ-A mouse AHR plasmid,
196ng/ μl; 1 μl EcoR I; 1 μl Knp I; 2 μl 10X BSA; 2 μl Reaction Buffer; 2 μl 10X RNaseA; 2 μl
dH2O, q.s. 20 μl). Gently tap to mix, then put in the 37℃ oven overnight. PCR was performed
using a Q5 DNA polymerase reaction (5 μl 5X reaction buffer; 2 μl 2.5 mMdNTPs; 1.3 μl 10uM
forward primer OL881; 1.3 μl 10 uM reverse primer OL882; 1 μl 0.1ng mouse AHR template;
0.3 μl Q5 DNA polymerase; 14.1 μl dH2O, q.s. 25 μl) in: (Hot Start) 98℃ for the 30s; 30 cycles
of 98℃ for 10s, 55℃ for 15s, 72℃ 2 minutes 30s; then 72℃ for 2 minutes, hold at 4℃
indefinitely. The aa108-400 human AHR was obtained from pPICZ-B hAHR by Polymerase
Chain Reaction. PCR was performed the same as mouse AHR except for the primers and
extension time (forward primer OL835, reverse primer OL836; extension time 60s). Primer’s
information is shown in Table 1.
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Table 1
Primer information for PCR, Colony PCR, RT-PCR.
Oligo (OL)
Number

Primer Sequence

OL835

pPICZ-B-pohAHR aa108-400
Forward primer 5’- taattattcgaaacgaggaattcac atg GAG GGT TTG AAC TTG
CAA GAG GGT G -3’

OL836

pPICZ-B-pohAHR aa108-400
Reverse primer 5’- ga tcc gag acg gcc ggc tgg gcc ac T AGT GTT TCT CTT TCT
CAA GTG CTC -3’

OL881

pPICZ-B-mAHR b1
Forward primer 5’- taattattcgaaacgaggaattcac atg TCC TCC GGT GCT AAC
ATC ACT TAC G -3’

OL882

pPICZ-B- mAHR b1
Reverse primer 5’- ga tcc gag acg gcc ggc tgg gcc ac A GGA CTG GAC CTT
AGA CAA GAA AGC -3’

OL896

Forward primer for detecting mAHR. (Locate at the beginning part).
5’- TCCTCCGGTGCTAACATCACTTAC-3’

OL897

Reverse primer for detecting mAHR. (Locate at the beginning + 200bp part).
5’- GGACAACTTGTCCAACT-3’

OL898

Forward primer for detecting hAHR aa108-400 and hAHR. (Locate at the
beginning of hAHR aa108-400).
5’-GAGGGTTTGAACTTGCAAGA -3’

OL899

Reverse primer for detecting hAHR aa108-400 and hAHR. (Locate at the
beginning of hAHR aa108-400 + 200bp part).
5’- TGTCTCTGGAACTCAGCTCT -3’

OL900

Forward primer for detecting hAHR aa108-400 and mouse AHR. 5’ccagagacaattgcactgggc-3’

OL901

Reverse primer for detecting hAHR aa108-400 and mouse AHR.
5’- ggtggctgcaatggagtagcga-3’

OL902

Forward primer for Pichia strain, use actin as reference. Copy number
determination by RT-PCR. Use with OL903.
5’-CCTGAGGCTTTGTTCCACCCATCT-3’

55

(Table 1 Continued)
OL903

Reverse primer for Pichia strain, use actin as reference.
5’-GGAACATAGTAGTACCACCGGACATAACGA-3’

Note. All primers were optimized for Pichia expression.

5.2.2 Gibson assembly reaction. Both cDNA (mouse AHR and aa108-400 human
AHR ) were cloned into Pml I site of pPICZ-B plasmid to generate pPICZ-cDNA plasmid by
Gibson assembly with PCR product of Pml I overhang primer. The cloned plasmid was used to
express a recombinant protein with c-myc and 6-His tags at the C-terminus. Gibson Assembly
Reaction was performed (1 μl 0.02pmol pPICZ-B Pml I; 9 μl 0.07pmol mouse AHR or aa108400 hAHR Pml I overhang; 2X Gibson assembly master mix) in thermocycler: 50℃ for 20
minutes, then 4℃ afterward.
5.2.3 Electro transformation. Dilute 2 μl Gibson mix with 4 μl Nuclease-free water
(1: 3) mix well, then use 1 μl of the diluted mixture for electroporation. The pPICZ-B mouse
AHR and pPICZ-B aa108-400 human AHR construct were propagated in BL21 cells to generate
a sufficient amount, respectively. Then the construct was linearized with Invitrogen
recommended Sac I enzyme, which only cuts at the plasmid sequence once but not the insert
before being transformed into the freshly prepared competent ySMD1163 Pichia pastoris strain
(a protease deficient Pichia strain) by electroporation using an Eppendorf 2510 electroporator,
according to the manufacturer’s recommendation. The preparation of competent ySMD1163
cells and yJC100 followed by Dr. Geoff Lin-Cereghino's lab protocol. In order to select the
Pichia cells, which containing the codon-optimized mouse AHR or aa108-400 human AHR gene
and stably integrated into the yeast genome, we incubated the Pichia cells in 1 mL of 1 M
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sorbitol at 30℃ shaking for one hour, followed by the addition of 1 mL of YPD media. Then the
resulting culture was plated onto a YPD plate containing Zeocin (100 μg/μl ~ 1000 μg/μl),
followed by 30℃incubation in a dark place for 2 ~ 4 days until the transformed yeast colonies
were formed.
5.2.4 Colony PCR. Colonies were then streaked to obtain individual colonies and grown
on another YPD plate containing Zeocin at 30 ℃ for 2 ~ 4 days. The newly formed colonies
were validated by colony PCR to confirm the presence of the gene by using appropriate primers.
Use OL896 and OL897 to detect the mouse AHR, OL898 and OL899 to detect the aa108-400
hAHR (Table 1).
5.2.5 Protein expression and purification. For a 100 mL Pichia expressed mouse AHR
or aa108-400 hAHR purification, the freshly prepared colony was inoculated in BMGY media
and incubated at 29℃ with rotation at 250 rpm until OD600 reached 2.5 absorbance units. A cell
suspension was centrifuged at 1,500 g for 5 min at room temperature. The resulting pellet was
washed twice with BMMY (50 mL) and then resuspended in 250 mL BMMY with 0.5%
methanol in a 1 L baffled flask to induce the mouse AHR expression for 6 h with rotation at 250
rpm at 29℃. The cell suspension was then centrifuged at 3,100 g for 5 min at 4℃. The
resulting cell pellet was washed with 20 mL of cold PBS and then centrifuged at 12,000 g for 5
min at 4℃. Resuspend the pellet (~6ml) with 5X pellet volume (~30ml) of lysis buffer (25mM
HEPES, pH 7.4, 0.3M KCl, 10% glycerol, and 300 μl 100X Gold protease inhibitor cocktail
GB108-2). Then aliquot lysate into 1.5ml Eppendorf tubes specifically for Bullet Blender
(ZrOBO5 beads ~ 0.2ml; Speed setting at 8 for 5 minutes, cool down for 5 minutes, and repeat
once). Spin at 16,000g for 20 minutes at 4℃, collect the supernatant. The resulting supernatant
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(Load), which has the Pichia expressed protein, was collected as the starting material for metalaffinity purification using cobalt resin. To purify the recombinant protein, 1 mL of cobalt resin
column was preconditioned by dH2O and lysis buffer, 2.6 ~ 2.8 ml Load (Pichia cell lysate
supernatant) was poured onto the 1 mL cobalt resin column at 4℃. The Load was passed
through the column 5 times and collected the Flow-through (FT) at the last time. Then wash the
column with 2.5 mL lysis buffer and collect the culture as Wash 1. Another 5 ml elution buffer
(add 0.1702 imidazole, the final imidazole concentration is 0.5M) with lysis buffer containing 20
mM imidazole was applied onto purification. To elute the protein bound to the resin, 5 mL of an
elution buffer containing was applied onto the column, and the eluate was collected. The
majority of the recombinant protein was captured in the first 1.5 mL of the eluates (E1). Elute 2
(E2) and elute 3 (E3) are also collected as follows.
5.2.6 Coomassie blue staining and Western blot analysis. Coomassie Blue staining
and Western blot analysis of SDS-PAGE were used to determine the presence and purity of the
purified proteins. The general Western blot analysis using a near-infrared detection method. Mix
the lysate sample 1:1 (v/v) with 1x treatment buffer. Vortex completely and heat at 95C for 1.53 min (depending on the volume of the samples). Briefly centrifuge to collect the samples at the
bottom, which is ready for SDS-PAGE. Minimize loading time to reduce the diffusion of
samples to avoid distortion of bands. Choose the percentage of the gel depending on the
molecular weight of target proteins. Pre-wet the filter paper and nitrocellulose membrane before
wet transfer. Proteins on the gel were transferred to a nitrocellulose membrane at 300 mA for
120 minutes at 4C, followed by a blocking step incubation in a blocking buffer (PBS containing
5% BSA) at room temperature for 1 h. Subsequently, the membranes were treated with primary
and secondary antibodies. Wash 5 minutes for 5 times with 1x PBST before proceeding to
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secondary antibody incubation. Anti-AHR SA210 (1: 5,000) and anti-c-myc (1: 5,000)
antibodies were used as primary antibodies diluted in blocking buffer and incubated overnight at
4℃. Secondary antibody incubation (LI-COR IRDye 800 donkey anti-rabbit IgG or donkey
anti-mouse, 1: 10,000) was performed in the blocking buffer for 2 h at room temperature. Wash
the membrane as previously, and the last time wash with cold PBS to lower the background
signal. The LI-COR Odyssey imaging system was used for detecting the results.
5.2.7 RNA extraction. Lyse cells with TRI reagent. Proceed to RNA Purification. Add
an equal volume of ethanol (95- 160 100%) directly to one volume sample in TRI. Mix well by
inverting and vortex. Load the mixture into a column in a collection tube. Centrifuge 30 sec.
Transfer the column into a new collection tube and perform in-column DNase I treatment. Wash
the column with 400 µL RNA Wash Buffer. Centrifuge 30 sec and discard the flow through.
Prepare DNase I reaction mix in a clean tube: 5 µL DNase I (6 U/µL), 75 µL DNA Digestion
Buffer for each tube. Mix by gentle inversion. Add 80 µL of the mix per column directly to the
column matrix. Incubate at room temperature for 15 min and then centrifuge for 30 sec. Add
400 µL Direct-zol RNA Prewash to the column and centrifuge for 30 sec. Discard the flowthrough and repeat this step. Add 700 µL RNA Wash Buffer to the column and centrifuge for 2
min to ensure complete removal of the wash buffer. Discard the flow-through and transfer the
column to an RNase-free tube. Add 50 µL DNase/RNase-free water directly to the column
matrix and centrifuge for 1 min. Quantify with nanodrop.
5.2.8 Reverse transcription. Denature the RNA samples and anneal the primers. For
each reaction, combine the following components on ice in a RNase-free 0.2 mL PCR tube: 10
µL total reaction volume = 0.4 µL random primer + 100 pg-1 µg (use 0.5-1 µg for lower Cq
number) + RNase-free water. Incubate at 65 C for 2 min and chill on ice (set as 4 C) for at
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least 1 min in the thermocycler. Briefly centrifuge and combine with the following components
on ice for one reaction (total volume would be 20 µL): 3 µL RNase-free water, 2 µL 10x
MMLV buffer, 2 µL 100 mM DTT, 0.5 µL ScriptGuard RNase inhibitor, 2 µL dNTP mix (2.5
mM), 0.5 µL MMLV high performance reverse transcriptase. Use the PCR thermocycler to 161
perform the protocol: 10 min room temperature followed by 37 C 60 min; terminate the reaction
by heating at 85 C for 5 min and then 4 C for at least 1 min. Centrifuge briefly. The cDNA
can be used immediately for real-time PCR or stored at -20 C for future use.
5.2.9 Quantitative PCR (qPCR). qPCR was performed with 1ul of cDNA from reverse
transcription solution, 10 µL of Bio-Rad iTaq SYBR green Supermix, and 0.8 pmol sequencespecific primers using a Bio-Rad CFX Connect real-time PCR machine with the following
protocol: 40 cycles of 90 C for 10 s/60 C for 1 min with fluorescence readings taken at 60 C.
5.3.0 Statistical analysis. GraphPad Prism 9 software (La Jolla, CA, USA) was utilized
for statistical analysis.
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